ViiV Poised To Take HIV PrEP Injectable In Late-Stage Trials
Executive Summary
ViiV Healthcare is set to start Phase III studies of its next-generation integrase inhibitor cabotegravir as a long-acting injectable for the prevention of HIV. The head-to-head study will compare it with Gilead’s market leading oral PrEP therapy Truvada in pre-exposure prohylaxis in both men and women.